Adeera Levin教授现任加拿大不列颠哥伦比亚大学(UBC)内科学教授、肾脏病学部主任,曾于2015–2017年担任国际肾脏病学会(ISN)主席,她是CKD、心肾代谢领域国际权威专家。在2026年美国肾脏病学会年会—肾脏周(ASN 2026)上,肾医线特邀Adeera Levin教授就相关问题分享了真知灼见。
一、CKM框架下肾病学家应重塑患者评估与管理方式
在ASN 2026上,Levin教授主持了作为"心血管-肾脏-代谢综合征中的肾脏照护优化(Optimizing Kidney Care in Cardiovascular-Kidney-Metabolic Syndrome)"专题会议。Levin教授认为,CKM框架应当改变肾病学家看待患者的方式,推动对其所照护患者全部风险的更整体化评估,并促进与初级保健及其他专科的更紧密协作。她指出,血压、血脂以及体重管理和血糖控制是需要重点关注的关键环节。
Nephrology on-line: As moderator of “Optimizing Kidney Care in Cardiovascular-Kidney-Metabolic Syndrome,” how do you think the CKM framework should change the way nephrologists assess and manage patients? Which aspects of cardiovascular and metabolic health deserve greater attention during routine kidney care?
Prof. Adeera Levin: the CKM framework should change the way that nephrologists view their patients, and promote a more holistic approach to assessment of all risks of those under our care, and foster more collaboration with primary care and other specialities. Attention to blood pressure, and lipids as well as weight management and glycemic control would be key things to attend to.
二、HFpEF合并CKD:以"内表型"评估驱动个体化治疗
在谈及HFpEF治疗范式演变时,Levin教授强调,对同时患有CKD的患者而言,最重要的变化在于通过定期评估症状、实验室指标及其他检查(如超声心动图[ECHO]、床旁超声[POCUS]等)来实现更丰富的"内表型"(endotyping)划分,从而据此制定个体化的药物启动策略。
换言之,肾功能、白蛋白尿、淤血状态与代谢合并症不应被孤立看待,而应整合进对患者整体表型的判断之中,用以确定治疗优先次序。
Nephrology on-line: In your presentation on evolving treatment paradigms in HFpEF, which changes do you consider most important for patients who also have CKD? How should kidney function, albuminuria, congestion, and metabolic comorbidities inform individualized treatment priorities?
Prof. Adeera Levin: I would suggest regular assessment of symptoms and evaluation of laboratory and other measures ( such as ECHO, POCUS etc) to enable more rich 'endotyping' of individuals which would then lead to a personalized approach to initiation of medications.
三、肾功能、血压、血钾波动:先理解病因,再决定调整
针对HFpEF合并CKD患者治疗中肾功能、血压或血钾变化给临床决策带来的困扰,Levin教授明确反对"单纯因实验室指标变化就条件反射性停药"的做法。
Levin教授认为,要改善对变化的病因的认识,并在具体情境中加以解读,需要回归对复杂相互作用背后生理学机制的更好理解。对实验室指标的变化应审慎评估,相比目前的临床现状,反射性停药的情形应当更少。
Levin教授同时提醒,下调其他药物剂量同样是可选方案之一。
Nephrology on-line: When treating patients with both HFpEF and CKD, changes in kidney function, blood pressure, or potassium can complicate treatment decisions. How should clinicians interpret these changes and decide when to continue, adjust, or temporarily interrupt therapy?
Prof. Adeera Levin: Improved appreciation of the etiology of the changes and interpretation in context requires return to improved physiology understanding of the complex interplay I do not think that reflex 'stopping of medication' because of laboratory changes should be critically evalauted, and be more rare than it currently is
Adjustments down of other medications is also an option.
四、联合诊疗:让基层医疗团队能够直接获得专科意见
谈到如何将上述理念落地到日常临床工作中,Levin教授指出,理想模式是开设联合门诊,围绕患者的需求配置医疗资源,而非以医生为中心。还可以建立相应的协作机制,使基层医疗团队在有疑问时直接向不同专科征求诊疗意见,而不仅仅是通过单次会诊的方式。她坦言,这些作法需要各卫生体系配套全新的照护模式与医保支付机制。此外,在条件允许时,医生也应能够获得药师、营养师、护士和社会工作者的支持。
Nephrology on-line: Bringing these themes into everyday practice, what would an effective collaboration between nephrology, cardiology, and primary care look like? For clinical teams with limited resources, which practical changes should be prioritized to improve continuity of care and long-term outcomes?
Prof. Adeera Levin: Ideally having combined clinics where resources are organized around the patient, not the MD would be ideal. MOdels where primary care can access different specialities for advice not simply consultation, would be ideal. These require different models of care and reimbursment in different health systems. In addition, the MDs should have access to pharmacists, dieticians, nurses and social workers where feasible.
总之,Levin教授认为,应以更整体的风险评估、更丰富的表型刻画和更审慎的实验室判读,替代碎片化、反射式的诊疗习惯;并以围绕患者组织的跨专科协作与团队支持,推动CKM综合征和HFpEF合并CKD患者照护的连续性与长期结局改善。
“肾医线”读者专属微信群建好了,快快加入吧。扫描“肾医线”小助手二维码(微信号:nephro-online),回复“肾医线读者”,ta会尽快拉您入群滴!
(来源:《肾医线》编辑部)
本文仅供医疗卫生专业人士了解最新医药资讯参考使用,不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导,也不应被视为诊疗建议,如果该信息被用于资讯以外的目的,本站及作者不承担相关责任。
我要留言